Warminster-based Arbutus Biopharma has cranked up its legal war over COVID‑19 vaccine delivery technology, rolling out a new round of international lawsuits on Thursday that target Pfizer and BioNTech. The company is seeking damages and court orders over alleged infringement of its lipid‑nanoparticle (LNP) patents. Arbutus, based in Bucks County, also told investors it received roughly $178 million this month from a settlement with Moderna and that it plans to return capital to shareholders, putting fresh heat on a multi‑year fight over the technology that helped make mRNA vaccines possible.
Arbutus and its exclusive licensee Genevant said they have filed three new actions, including two cases at the Unified Patent Court and a separate case in Canada, seeking permanent injunctions and monetary relief for alleged infringement of European and Canadian LNP patents, according to GlobeNewswire. The UPC filings list case numbers PR‑UPC‑CFI‑0002562/2026 and PR‑UPC‑CFI‑0002566/2026 and identify EP 4 241 767 and EP 4 495 237 as the asserted patents, which cover more than a dozen EU member states. According to the release, the new actions extend the companies' ongoing U.S. enforcement efforts in the District of New Jersey.
How the Suits Widen the Fight
The overseas filings build on a U.S. complaint Arbutus and Genevant brought in April 2023 in the District of New Jersey, where they are asserting five U.S. patents that cover LNP composition, manufacture and delivery. That U.S. case has already been through claim‑construction hearings, and the companies say several rulings in 2025 resolved key disputed terms in their favor, as described in Arbutus' public filings. Those earlier decisions set up the legal framework that the new international actions now try to carry across borders.
Why the Cases Matter
If European courts ultimately grant the permanent injunctions Arbutus is asking for, the orders could limit Pfizer and BioNTech's ability to sell Comirnaty or related LNP‑based products in multiple EU markets, a commercially meaningful threat given Comirnaty's market share. Pfizer and BioNTech have responded with revocation efforts and other challenges in both Europe and the United States, signaling how fiercely the underlying patent claims are disputed, as reflected in BioNTech filings.
Local and Shareholder Fallout
Arbutus said it received approximately $178 million on July 8 as its share of Moderna's non‑contingent payment under a March settlement, and the company expects a dividend from Genevant's parent in the third quarter. It has told investors it plans to return up to roughly $230 million to shareholders through repurchases. The same disclosure shows the board signed off on special one‑time bonuses tied to the litigation proceeds, a move that puts a spotlight on how management intends to handle its legal windfall.
What Comes Next
Lawyers and industry analysts say these kinds of patent fights can drag on for years, with patent oppositions, inter partes reviews and appeals all on the table before any EU injunctions or U.S. judgments become final. The Moderna settlement closes out one major front in the LNP legal battles but leaves the high‑stakes Pfizer/BioNTech clash as the main unresolved showdown, a dynamic observers have called out in broader coverage of the settlement and its ripple effects on the vaccine industry.
Closer to home, the latest filings highlight just how much Warminster is punching above its weight in a global intellectual‑property brawl. A relatively small Bucks County firm and its licensee are pressing claims that could influence vaccine markets around the world. That international reach, and Arbutus' Warminster headquarters, were noted in coverage by the Philadelphia Business Journal.
